- Earlier this week, n-Lorem Foundation announced an early-stage research collaboration and exclusive global licence agreement with BioMarin Pharmaceutical to develop an investigational antisense oligonucleotide <a href="https://healthylife7.com/dmd-cell-therapy-delays-disease-progression-in-phase-iii-trial/” title=”DMD Cell Therapy Delays Disease Progression in Phase III Trial”>therapy for ReNU syndrome, with preclinical work underway and plans for future clinical studies.
- A key aspect of the deal is BioMarin’s intention to develop the medicine for broader use across the ReNU syndrome community, aiming to address an estimated 75% of cases and potentially widening its rare disease portfolio.
- We’ll now examine how this ReNU syndrome antisense collaboration could influence BioMarin’s rare disease pipeline thesis within its broader investment narrative.
Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge
Advertisement
BioMarin Pharmaceutical Investment Narrative Recap
To own BioMarin, you generally need to believe its focus on high unmet-need rare diseases can translate into durable demand and a steadily broadening portfolio. The ReNU antisense collaboration fits this thesis thematically, but it is very early and does not materially change the near term picture, where VOXZOGO regulatory milestones and pricing and reimbursement pressures on the core portfolio remain the key catalyst and the biggest risk
Among recent announcements, the FDA’s acceptance of BioMarin’s VOXZOGO supplemental NDA for full approval in achondroplasia is most relevant. It underscores how central skeletal growth disorders remain to the investment case and highlights ongoing regulatory risk: confirmatory data, evolving endpoints and payer scrutiny will likely matter far more to results over the next few years than early stage programs like the ReNU antisense candidate
But while new programs like ReNU might broaden the future, investors should also be aware of the risk that concentrated exposure to VOXZOGO and PALYNZIQ
Read the full narrative on BioMarin Pharmaceutical (it’s free!)
BioMarin Pharmaceutical’s narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029. This requires 14.8% yearly revenue growth and an earnings increase of about $1.0 billion from $268.7 million
Uncover how BioMarin Pharmaceutical’s forecasts yield a $87.85 fair value, a 43% upside to its current price
Exploring Other Perspectives
While this ReNU news may support the rare disease pipeline story, the most bearish analysts still assume only about US$4.5 billion revenue and US$752.9 million earnings by 2029, reminding you that expectations can differ sharply and are worth comparing
Explore 4 other fair value estimates on BioMarin Pharmaceutical – why the stock might be worth over 4x more than the current price!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own
- A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate BioMarin Pharmaceutical’s overall financial health at a glance.
Looking For Alternative Opportunities?
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
- Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:BMRN
BioMarin Pharmaceutical
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally
See The Free Research Report
Flawless balance sheet and fair value
See The Free Research Report
Similar Companies
NasdaqGS:AMGN
Amgen
NasdaqGS:VRTX
Vertex Pharmaceuticals
Market Insights
Why 2026’s worst-looking sector might be its most misreadMitchell Lawler
A brand’s strength doesn’t always lastRichard Bowman
What makes a lasting brand?Andrew Legget
Advertisement
Weekly Picks
CE
Ceazaron Sparc AI·3 months ago
When GPS fails: this small cap is fixing a $54B drone problem
Fair Value:CA$5.2554.7% undervalued
108followersusers have followed this narrative
·0commentsusers have commented on this narrative
·24likesusers have liked this narrative
BL
BlackGoaton IREN·13 days ago
IREN’s Bold Moves in Sustainable Bitcoin Mining & AI Data Centers
Fair Value:US$71.4859.0% undervalued
213followersusers have followed this narrative
·8commentsusers have commented on this narrative
·32likesusers have liked this narrative
HE
HedgeYon Arm Holdings·15 days ago
The Architecture Layer of AI Computing – But Priced Like the Future Already Arrived?
Fair Value:US$43047.7% undervalued
20followersusers have followed this narrative
·1commentusers have commented on this narrative
·6likesusers have liked this narrative
HI
Hidden_Rock_Capitalon Fiserv·28 days ago
Temporary “perfect storm” leads to opportunity to buy financial services leader for less than 5x long-term earnings
Fair Value:US$119.9953.6% undervalued
25followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
RecentlyUpdated Narratives
SI
simplydunnoon Microsoft·about 3 hours ago
Microsoft’s Capex Bill Comes Due Before the AI Revenue Does
Fair Value:US$512.123.7% undervalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
HE
Henrynuke03on Nigerian Exchange Group·about 12 hours ago
Future Growth Awaits NGXGROUP with New High-Profile Listings
Fair Value:₦221.1732.3% undervalued
7followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
PR
PrashhDon Aurionpro Solutions·about 16 hours ago
Aurionpro Solutions: Is the Market Mispricing One of India’s Most Interesting Fintech Product Companies?
Fair Value:₹1k27.1% undervalued
1followerusers have followed this narrative
·1commentusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·about 2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28032.1% undervalued
211followersusers have followed this narrative
·9commentsusers have commented on this narrative
·15likesusers have liked this narrative
CUCubanEroson Microsoft·26 days ago
A wonderful business at reasonable price
Fair Value:US$419.917.0% undervalued
97followersusers have followed this narrative
·0commentsusers have commented on this narrative
·7likesusers have liked this narrative
BE
benjamin_lvieqon PayPal Holdings·14 days ago
PayPal: PayPal Doesn’t Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6510.2% undervalued
74followersusers have followed this narrative
·2commentsusers have commented on this narrative
·11likesusers have liked this narrative
